Deutsche Bank Starts Aegerion Pharmaceuticals (AEGR) at Buy; See Approval in 2012 Likely for Lomitapide

Deutsche Bank initiates coverage on Aegerion Pharmaceuticals (NASDAQ: AEGR) with a Buy. PT $19.00.

Deutsche analyst says, "Aegerion belongs to a group of biotech companies that are categorized as "orphan drug" companies because they develop & sell drugs for very rare diseases (<200KUS patients). Aegerion is developing a pill, Lomitapide, for a rare disease called HoFH that is associated with high cholesterol levels and early death. We rate the stock a Buy because we believe the current stock price does not reflect full FDA approval or the full potential for Lomitapide in HoFH and FC. Next catalysts: long term 78 week data YE2011, FDA approval mid 2012."

For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.

Shares of Aegerion Pharmaceuticals closed at $14.97 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Barclays Starts Centrus Energy Corp. (LEU) at Equalweight
• Morgan Stanley Starts eMemory Technology Inc (3529:TT) at Overweight
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform